Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

2009.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements interpreting the results of the Company's Phase 2 clinical trial of picoplatin in metastatic colorectal cancer and describing the Company's regulatory and partnering strategies with respect to such product candidate. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials, including the Phase 2 trial described in this press release; the results and timing of the Company's discussions with the FDA; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to attract and retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation a
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Ascletis announced today the completion ... investment was led by C-Bridge Capital, joined by Tasly ... The valuation of the Company before financing was US$300 ... be used to expand Ascletis, pipeline, strengthen global development ... the support of the investors, Ascletis is now entering ...
(Date:9/2/2015)... Sept. 2, 2015  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... immunotherapies, announced today that members of its leadership team ... September, including: , First World Congress ... and Food & Environmental Technologies; Portoroz, Slovenia ... Global Investment Conference; New York, NY ...
(Date:9/2/2015)... YORK , Sept. 2, 2015   Americord Registry ... , and placenta tissue banking company, announced today ... 2015 Inc. 500. Logo - http://photos.prnewswire.com/prnh/20150902/263095LOGO ... honorees had to have grown at least tenfold over the ... 2011 and has continued this trend with 50% quarterly growth ...
Breaking Medicine Technology:Ascletis Secures US$35 Million Financing 2Ascletis Secures US$35 Million Financing 3OncoSec to Present at Scientific and Investment Conferences in September 2OncoSec to Present at Scientific and Investment Conferences in September 3OncoSec to Present at Scientific and Investment Conferences in September 4OncoSec to Present at Scientific and Investment Conferences in September 5Americord Registry Announces Ranking on 2015 Inc. 500 2
... Levels With Doses an Order of Magnitude Lower than ... , , BETHESDA, Md., June 24 Spherix ... diabetes therapy, and a provider of technical and regulatory ... today announced positive preliminary results from a Phase 2 ...
... comply with recent FDA guidance for earlier testing-- ... Covance Inc. today announced ... Food and Drug Administration (FDA) guidance on Metabolites in ... human absorption, metabolism and excretion (AME) testing in support ...
Cached Medicine Technology:Spherix Announces Positive Phase 2 Study Results 2Spherix Announces Positive Phase 2 Study Results 3Spherix Announces Positive Phase 2 Study Results 4Spherix Announces Positive Phase 2 Study Results 5Spherix Announces Positive Phase 2 Study Results 6Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies 2Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies 3
(Date:9/2/2015)... Norcross, GA (PRWEB) , ... September 02, 2015 ... ... Aflac Cancer Center at Children's Healthcare of Atlanta to help support ... C.H.O.A. to discuss the upcoming WSB Radio Care-A-Thon , which is the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and ... HCPro and Associate Director of Education for the Association for Clinical Documentation Improvement Specialists ... for CDI Boot Camps. She serves as a CDI subject matter expert for a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... is taking action after seeing a significant increase in unlawful tactics used ... division has found many cases of OON ASCs encouraging members to have elective ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Every year at ... others dread it. However, few are prepared to face the academic workload confronting them. ... Our schools haven’t prepared them since schools don’t teach students how to study. , ...
Breaking Medicine News(10 mins):Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3
... of Queensland believe that the conotoxins present in the ... from chronic pain//. This treatment could replace the conventional ... say that the toxin, snail uses to hunt its ... effects usually caused by other pain treatments. ...
... easily available to critically ill patients. The Food and Drug ... who are extremely ill to try out experimental drugs when ... FDA has announced that they will consider the prices that ... to needy individuals .They will also clarify the norms and ...
... by researchers from University of Sydney suggested that having ... problems in breastfeeding//. The study results were published in ... ,Researchers, who studied 1,300 women who gave birth ... have the anaesthetic are more likely to have problems ...
... for the American public. A decade after genetically altered ... remain ignorant and disinclined towards them. ,According to ... and Biotechnology, the last five years have seen little ... ,Says executive director of the survey’s sponsor, Michael ...
... conducted at the Auckland Aquatic Center in Henderson. //Six 12 ... at the West Wave Aquatic Centre on Dec 10. The ... be admitted in the hospital. ,Waitakere City Council ... concerned by what had occurred and investigations are continuing into ...
... effective as popular sports drinks and gels in maintaining ... endurance athletes who participated in a study by researchers ... study results were reported as a poster presentation at ... American College of Sports Medicine in San Diego last ...
Cached Medicine News:Health News:Gene-Altered Foods -Still Not Sure 2Health News:Sports-Formulated Jelly Beans Just as Effective as Sports Drinks 2
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... known as bone Gla protein, is a ... a major component of the noncollagenous bone ... in bone, with a small amount produced ... [1]. During bone formation, newly synthesized osteocalcin ...
... Protein-1 (IGFBP-1) is a phosphoprotein, produced primarily ... modulates the bioactivity of IGF-I and IGF-II ... been completely defined, but the nature of ... involved in glucose regulation and IGF-mediated substrate ...
Medicine Products: